Thank you - well said! Sue From: avaplmembers-bounce@xxxxxxxxxxxxx [mailto:avaplmembers-bounce@xxxxxxxxxxxxx] On Behalf Of Junginger, John A. Sent: Tuesday, August 10, 2010 12:46 PM To: Joan.Zweben@xxxxxxxx; Lemle, Russell Cc: members1@xxxxxxxxx; VHA Psychology Postdoctoral Training Directors; VHA Psychology Internship Directors; VHA National Psychology Chiefs; V21SFC Psychologists; Armstrong, Keith Subject: [AVAPL Members] Re: How to Improve the Implementation of Evidence-Based Psychotherapy in the VA It seems to me that VACO has every right to develop special productivity measures, both in recognition of the additional effort involved in administering EBPs and as an incentive for their adoption by local sites. The thing is, if you're going to put this kind of time, effort and $ into what many of us see as an extremely worthwhile initiative, you'd better have some carrots in place to make participation immediately worthwhile for the service providers. As for Dr. Zweben's other points: * I don't have a good enough sense of the collaborative process to comment, but the process certainly has been transparent-at least from our lofty view here in Central Iowa. If that's not the opinion of others, then maybe another summary of the selection process in this forum would be helpful. * CBT, PE, CPT, ACT & SST all have solid empirical support-no mystery there, ...and this from a person who loves a good mystery. Thus, the statement that treatments with weak evidence were selected while others with strong evidence were omitted seems a bit misleading. Which EBPs with similarly strong empirical support were overlooked? * Hard to argue with any proposal of a multi-site effectiveness study conducted on VA populations for a variety of EBPs. But, honestly, how realistic is that? Patricia Resick briefly reviewed for us last week the compelling evidence for CPT for Veterans with PTSD, so that's one bit of relevant information that should not be ignored in these exchanges. I also think it's an arguably small leap-of-faith to expect demonstrably positive outcomes with the other EBPs included in the VACO rollout given their strong empirical support for other populations. * The MH profession never did degenerate to "cookie cutter" treatment, so there's really no risk of returning; it's one of those bogeymen we're often warned about, but which never seem to appear. Maybe more to the point, EBPs are nothing if not "individualized." That is, their parameters, elements of focus and treatment paths are continually adjusted to fit the characteristics of the problem being addressed. Don't know how this cookie cutter myth took hold, but it's time to dismiss it out-of-hand. * I can see how an emphasis on empirically supported treatments might be inferred as a de-emphasis on the therapeutic relationship. But (and I'm going out on a limb here), has any of us ever heard an EBP advocate dismiss the therapeutic relationship? Really? If anything-and this certainly was true of the VACO EBP rollout last year in Nashville-EBP advocates seem to go out of their way to acknowledge its importance. So, while I'm willing to admit that maybe I haven't noticed some slights to the therapeutic process, they must have been few and far between and clearly are not representative of evidence-based philosophy or policy. VACO's EBP rollout mostly is a "Bang for the Buck" proposition (wouldn't you say?) And, as with all such propositions, it's easy to second guess the numerous decisions that had to be made. That can be useful, but only to the extent that it helps move along the effort to deliver EBPs to our Veterans. John From: Joan E. Zweben, Ph.D. [mailto:Joan.Zweben@xxxxxxxx] Sent: Monday, August 09, 2010 8:44 PM To: Lemle, Russell Cc: members1@xxxxxxxxx; VHA Psychology Postdoctoral Training Directors; VHA Psychology Internship Directors; VHA National Psychology Chiefs; V21SFC Psychologists; Armstrong, Keith Subject: Re: How to Improve the Implementation of Evidence-Based Psychotherapy in the VA Dear Colleagues, I am writing to urge delay and open discussion of proposed RVU Productivity Incentives that would discourage the use of a broad range of efficacious treatments that have not been officially sanctioned. Crucial steps in the science appear to have been omitted. These include describing current outcomes as a baseline, conducting effectiveness studies to examine whether the list of treatments selected actually improve outcomes significantly for the VA patient population, and an examination of whether the level of improvement warrants the costs of implementation. Instead, it appears that the push for implementation goes beyond what is supported by the research. I am in support of Russell Lemle's proposal to include a wide range of efficacious treatments until these basic parameters have been established. I have been a part time substance abuse psychologist at the San Francisco VAMC for over 35 years. In the rest of my work life, I am the Executive Director of East Bay Community Recovery Project in Oakland. EBCRP has been part of NIDA's Clinical Trials Network since 2002. I have been on the CTN National Steering Committee throughout that time and am currently its Co-Chair. Throughout my long career, I have published both books and articles intended to foster the utilization of research findings by clinicians. This is a topic near and dear to my heart, and I am very concerned about the direction the VA has taken. Here are my concerns: * The process was neither collaborative nor transparent. This is guaranteed to create many problems in implementation, not the least of which is undermining confidence whether treatment outcomes will actually be improved. * Treatments with weak evidence were selected while others with strong evidence were omitted. Without transparent criteria and an open process, the rationale is mysterious and there is too much room for personal preferences of the decision makers. * To my knowledge, there are no multi-site effectiveness studies conducted on VA populations for the designated treatments, so we don't know much about the level of improved outcomes that can be expected. In general, effectiveness is reduced when treatments are implemented in real world situations, and in many case, the effect sizes in the random assignment studies are modest. How was it determined that the effect sizes were worth the transition costs? * The "pick from this list" approach stifles innovation and rigidifies the treatment system. It can promote a return to cookie-cutter treatment, rather than individualized treatment. * It appears that no attention has been given to the consistent research finding that the therapeutic relationship has a more powerful influence than any specific intervention in determining outcomes. The key question remains, how will we know if we will get better outcomes than some programs get now? An alternative approach is to look at our current outcomes, determine which programs have the best outcomes (excluding the possibility to significant differences in patient characteristics) and examine what they are doing that is working. A clear understanding of program strengths and weak spots also allows administrators and clinical staff to select from the array of evidence-based interventions or treatments to bring improvement in needed areas. NIATx (www.NIATx.net <http://www.niatx.net/> ) offers a simple process to help program units identify problems, make a plan for improved services, evaluate and fine tune that plan. I also suggest including experts such as William R. Miller, Ph.D., Tom McLellan, Ph.D., and Dean Fixsen, Ph.D. if this has not already been done. They have vast experience looking at the implementation of EBPs in the community and would have much wisdom to contribute to this process. Sincerely, Joan Zweben, Ph.D. Staff Psychologist, San Francisco VAMC Executive Director East Bay Community Recovery Project; Oakland, CA. Clinical Professor of Psychiatry, University of California, San Francisco. -- Joan E. Zweben, Ph.D. 714 Spruce Street Berkeley, CA 94707 Phone: (510) 526-4442 Fax: (510) 527-6842